Compare · DFTX vs PRDS
DFTX vs PRDS
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Pardes Biosciences Inc. (PRDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and PRDS operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $2.64B, about 4.0x PRDS ($657.5M).
- DFTX has hit the wire 10 times in the past 4 weeks while PRDS has been quiet.
- DFTX has more recent analyst coverage (4 ratings vs 3 for PRDS).
- Company
- Definium Therapeutics Inc.
- Pardes Biosciences Inc.
- Price
- $24.15+1.62%
- $2.19+1.39%
- Market cap
- $2.64B
- $657.5M
- 1M return
- +15.11%
- -
- 1Y return
- +259.91%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 10
- 0
- Recent ratings
- 4
- 3
PRDS
Pardes Biosciences Inc.
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
Latest DFTX
- SEC Form S-8 filed by Definium Therapeutics Inc.
- Director Vallone Carol A was granted 4,666 shares, increasing direct ownership by 28% to 21,210 units (SEC Form 4)
- Director Crystal Roger was granted 4,666 shares, increasing direct ownership by 24% to 24,289 units (SEC Form 4)
- Director Gryska David W was granted 4,666 shares, increasing direct ownership by 31% to 19,900 units (SEC Form 4)
- Director Adsett Roger was granted 3,555 shares (SEC Form 4)
- Director Krebs Andreas was granted 4,666 shares, increasing direct ownership by 31% to 19,773 units (SEC Form 4)
- Director Bruhn Suzanne Louise was granted 4,666 shares, increasing direct ownership by 24% to 24,289 units (SEC Form 4)
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Definium Therapeutics Announces New Employee Inducement Grants
Latest PRDS
- SEC Form 15-12G filed by Pardes Biosciences Inc.
- SEC Form EFFECT filed by Pardes Biosciences Inc.
- SEC Form EFFECT filed by Pardes Biosciences Inc.
- SEC Form 4: Tananbaum James B. returned 16,813,146 shares to the company and acquired 1,000 shares
- SEC Form SC 13D/A filed by Pardes Biosciences Inc. (Amendment)
- SEC Form 4: Wiggans Thomas G closing all direct ownership in the company
- SEC Form 4: Varney Michael David closing all direct ownership in the company
- SEC Form 4 filed by Smaldone Alsup Laurie
- SEC Form 4 filed by Pottage John C Jr
- SEC Form 4: Lopatin Uri A closing all direct ownership in the company